

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer
 - a. Patient has had a complete or partial response to platinum-based chemotherapy
 - b. *BRCA*-positive mutation
2. Advanced epithelial ovarian, fallopian tube or primary peritoneal cancer
 - a. Patient has had a complete or partial response to platinum-based chemotherapy and **ONE** of the following:
 1. *BRCA*-positive mutation
 2. Used in combination with bevacizumab
 - a. Cancer is associated with homologous recombination deficiency (HRD) positive status defined by at least **ONE** of the following:
 - i. Deleterious or suspected deleterious *BRCA* mutation
 - ii. Genomic instability
3. Early breast cancer
 - a. High risk
 - b. *BRCA*-positive mutation
 - c. HER2-negative
 - d. Previously treated with neoadjuvant or adjuvant chemotherapy
4. Metastatic breast cancer
 - a. *BRCA*-positive mutation
 - b. HER2-negative
 - c. Prior therapy with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting
 - d. If HR-positive must have **ONE** of the following:
 - i. Previously been treated with prior endocrine therapy
 - ii. Considered an inappropriate candidate for endocrine therapy

**LYNPARZA
(olaparib)**

5. Metastatic pancreatic cancer
 - a. *BRCA*-positive mutation
 - b. Disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen
6. Metastatic castration-resistant prostate cancer (mCRPC) and **ONE** of the following:
 - a. Homologous recombination repair (HRR) gene mutation
 - i. Disease progressed following prior treatment with enzalutamide or abiraterone
 - ii. Patient has had a bilateral orchiectomy **OR** patient will be receiving a gonadotropin-releasing hormone (GnRH) analog concurrently
 - b. *BRCA*-positive mutation
 - i. Used in combination with abiraterone
 - ii. Used in combination with prednisone or prednisolone
 - iii. Patient has had a bilateral orchiectomy **OR** patient will be receiving a gonadotropin-releasing hormone (GnRH) analog concurrently

Prior - Approval Limits**Quantity**

Strength	Quantity
100 mg	360 tablets per 90 days
150 mg	

Duration 12 months

Prior – Approval *Renewal* Requirements**Age** 18 years of age or older**Diagnoses**Patient must have **ONE** of the following:

1. Recurrent or advanced epithelial ovarian, fallopian tube or primary peritoneal cancer
2. Metastatic breast cancer
3. Metastatic pancreatic cancer
4. Metastatic castration-resistant prostate cancer (mCRPC)



Federal Employee Program.

LYNPARZA (olaparib)

AND the following for all indications:

- a. **NO** disease progression or unacceptable toxicity

Prior - Approval *Renewal* Limits

Same as above*

***NO** renewal for early breast cancer